GlobeNewswire Inc | Jan 4, 2022 07:00AM EST

January 04, 2022

WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the H.C Wainwright BioConnect Virtual Conference, being held on January 10-13, 2022.

The prerecorded presentation will become available on Monday, January 10, 2022 at 7:00 am ET and can be accessed by visiting the Investors page under the Events & Presentation section of the Prelude website, where a replay of the presentation will be available for a limited time.

About Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative, potential best-in-class molecules targeting critical cancer cell pathways involved in cancer pathogenesis. Preludes initial clinical candidates, PRT543 and PRT811, are potent, selective, oral PRMT5 inhibitors in Phase 1 development for the treatment of advanced solid tumors, primary and secondary CNS cancers and select myeloid malignancies. PRT1419, a potent and selective MCL1 inhibitor, is in Phase 1 development for patients with relapsed/refractory hematologic malignancies and solid tumors. PRT2527, a highly selective CDK9 inhibitor, is anticipated to begin Phase 1 clinical development by year-end as a monotherapy in patients with selected solid tumors. In addition, the Companys pipeline includes PRT-SCA2, a SMARCA2 protein degrader, PRT-K4, a highly selective kinase inhibitor, and additional discovery stage programs.

Investor Contacts:Stacey JurchisonExecutive Director, Corporate Affairssjurchison@preludetx.com

Melissa ForstArgot Partners212.600.1902prelude@argotpartners.com

Media Contact:Paige DonnellyArgot Partners212.600.1902prelude@argotpartners.com